Short answer
LifeMD, Inc. (LFMD) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $12.5 million secured loan closed November 9, 2026, refinancing Citizens Bank facility with no outstanding balance.
LifeMD, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $12.5 million secured loan closed November 9, 2026, refinancing Citizens Bank facility with no outstanding balance
- Variable interest rate, minimum 11.50%, with interest-only payments for up to 24 months
- Maturity May 1, 2030, plus 3.50% final payment and 1.00% to 3.00% prepayment penalties
- Warrants for $625,000 of common stock, potentially 269,376 shares at $2.32, or lower before June 30, 2027
- Quarterly covenant requires trailing twelve-month net revenue of at least $150 million, beginning December 31, 2026
Item 2.02 · Results of Operations and Financial Condition
- Press release announces LifeMD financial results for Q3 2026, three months ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, outlook, and operating metrics driving valuation
Item 3.02 · Unregistered Sales of Equity Securities
- Item 3.02 covers unregistered warrant issuance by LifeMD
- Warrant terms and sale details appear in Item 1.01
- Investors should assess potential dilution and warrant-related obligations using Item 1.01 terms
Item 7.01 · Regulation FD Disclosure
- Investor presentation made available November 12, 2026 for meetings with investors, analysts and other stakeholders
- Exhibit 99.2 contains management’s current strategy, outlook and operating priorities
- Presentation may influence investor expectations, but requires review of Exhibit 99.2 for substantive financial metrics and targets
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $44.6M, down 7% YoY, while adjusted EBITDA deteriorated to a $0.4M loss from $2.8M profit
- Subscriber growth remained solid at 350,000, up 13% YoY, despite marketing expense falling 34% sequentially to $18.5M
- Full-year 2026 guidance cut to $188M-$191M revenue and adjusted EBITDA loss of $10.6M-$12.6M
- Branded GLP-1 dispensing partnerships with Novo Nordisk and Eli Lilly expand pharmacy opportunity, but increase inventory and working-capital needs
- AT&T partnership provides access to 100M customers and 110,000 employees, creating a sizable enterprise distribution channel yet to ramp materially
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LifeMD, Inc. 8-K filings
Get the next LFMD 8-K as it lands
Follow LFMD for push alerts, or ask the research agent what this filing means.